Invivyd Forms SPEAR (Spike Protein Elimination and Recovery) Study Group with Researches to Assess Effects of Monoclonal Antibody Therapy for Long COVID
Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction
REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...
Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction
REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...
Water-Cooled Systems Drive 4.4% CAGR Growth as Process Cooling Demand Surges Across Chemical, Pharmaceutical, and Manufacturing Industries Worldwide
REDDING, Calif., June 27, 2025 /PRNewswire/ ---...
Water-Cooled Systems Drive 4.4% CAGR Growth as Process Cooling Demand Surges Across Chemical, Pharmaceutical, and Manufacturing Industries Worldwide
REDDING, Calif., June 27, 2025 /PRNewswire/ ---...
Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across Global Markets
REDDING, Calif., June 27, 2025 /PRNewswire/ -- The...
Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across Global Markets
REDDING, Calif., June 27, 2025 /PRNewswire/ -- The...
Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...
COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpox vaccine in vulnerable populations: infants under 2 years of age and pregnant and breastfeeding women